Biohaven Ltd. (NYSE:BHVN) Position Increased by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 202.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 34,165 shares of the company’s stock after purchasing an additional 22,858 shares during the quarter. Intech Investment Management LLC’s holdings in Biohaven were worth $1,276,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. HighTower Advisors LLC boosted its holdings in Biohaven by 6.1% during the fourth quarter. HighTower Advisors LLC now owns 5,870 shares of the company’s stock worth $219,000 after buying an additional 335 shares in the last quarter. Franklin Resources Inc. boosted its stake in Biohaven by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after purchasing an additional 412 shares during the period. KBC Group NV grew its position in Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after purchasing an additional 443 shares in the last quarter. FSC Wealth Advisors LLC grew its position in Biohaven by 3.3% during the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares in the last quarter. Finally, Amalgamated Bank grew its position in Biohaven by 21.9% during the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after purchasing an additional 527 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BHVN shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. JPMorgan Chase & Co. lowered their price objective on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Morgan Stanley lowered their price objective on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Biohaven in a research report on Tuesday, February 11th. They set a “buy” rating and a $65.00 price objective on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Biohaven currently has an average rating of “Buy” and an average target price of $63.15.

Insider Buying and Selling

In other Biohaven news, Director John W. Childs acquired 29,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the acquisition, the director now owns 2,368,741 shares of the company’s stock, valued at approximately $85,132,551.54. This trade represents a 1.24 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Trading Up 1.5 %

Shares of NYSE:BHVN opened at $28.61 on Friday. The stock has a market capitalization of $2.92 billion, a PE ratio of -3.06 and a beta of 1.27. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $59.53. The firm has a fifty day moving average price of $35.89 and a 200 day moving average price of $41.60.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.